In particular, subsets of NSCLC, defined by specific mutations in the epidermal growth factor receptor (EGFR) gene15, can be treated with Tyrosine Kinase Inhibitors (TKIs), including Gefitinib, Erlotinib and Afatinib, by achieving tumor response rate of 70–80% and progression free survival of 10 to 14 months16. The gene discussed is EGFR; the disease is neoplasm.